CVCureVac N.V. CVAC · NASDAQ
$4.64 -0.75% (-$0.04)
- Market cap
- 898.1M €
- Enterprise value
- 541.5M €
- P/E
- 4.6x
- Forward P/E
- -
- PEG
- -
- P/S
- 1.8x
- P/FCF
- 4.6x
- EV/EBITDA
- -
- ROIC
- 39.0%
- Gross margin
- 95.0%
- Net margin
- 37.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 2.6x
- Beta
- 1.84
- Free float
- 42.6%
About the company
CureVac N.V. (CVAC) is a biotechnology company focused on developing innovative drugs and therapies based on messenger RNA (mRNA) technology. The company is dedicated to researching and developing medicines and vaccines targeting various diseases, including infectious diseases, cancer, and other health conditions. CureVac plays a pivotal role in the field of mRNA technology development and its potential in disease treatment and prevention. Their mRNA vaccine against infectious diseases gained significant attention during the COVID-19 pandemic. Shares of CureVac N.V. (CVAC) can be an interesting choice for investors tracking the biotechnology sector and innovations in the field of drugs and vaccines.
Sector
Healthcare
Industry
Biotechnology
CEO
Alexander Zehnder
Employees
825
Headquarters
Tübingen
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number